Loading...

PHRV

PHVS

PHARVARIS NV

(PHVS)

2024 6-K

Financial Results Update

12 May '26

Share Offering Announcement

11 May '26

Financial Results Report

2 Apr '26

Investor Presentation Update

12 Jan '26

Positive Study Results

3 Dec '25

Financial Update

12 Nov '25

Registration Rights Agreement

8 Sep '25

Financial Update

12 Aug '25

Stock Offering Details

24 Jul '25

Study Data Update

10 Jul '25

Annual Meeting Results

27 Jun '25

Annual Meeting Announcement

10 Jun '25

Financial Update

13 May '25

Q4 Financial Results

7 Apr '25

Investor Presentation Update

13 Jan '25

Financial Update

13 Nov '24

Management Change

25 Sep '24

License Agreement Update

23 Sep '24

Business Update

5 Sep '24

Financial Results Update

14 Aug '24

Annual Meeting Results

28 Jun '24

Annual Meeting Notice

11 Jun '24

Press Release Issued

4 Jun '24

Financial Results Report

8 May '24

Financial Results & CFO

10 Apr '24

Shareholder Meeting Results

6 Mar '24

Shareholder Meeting Notice

16 Feb '24

Registration Rights Agreement

7 Feb '24

Corporate Presentation

22 Jan '24

Investor Presentation Launch

8 Jan '24

External Links:

SEC

On September 20, 2024, Pharvaris N.V. amended its license agreement with AnalytiCon Discovery GmbH, clarifying royalty obligations for specific drug compounds related to the treatment of hereditary angioedema. This filing is significant for the company as it pertains to exclusive rights on major drug products.

AI Assistant

PHARVARIS NV

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.